RESUMO
MicroRNAs (miRNAs) control liver diseases, but the role of microRNA-181a-5p in acute liver failure (ALF) is unclear. In this study, the ALF model was generated by injection of D-galactosamine (D-GalN) and lipopolysaccharide (LPS). The levels of miRNAs were assessed by microarray and qRT-PCR. The expression of caspase 3 was detected as the marker of cell apoptosis in ALF by immunohistochemistry and western blot. The targeting of microRNA-181a-5p on the high mobility group box 1 (HMGB1) was verified by dual luciferase assay. The impact of microRNA-181a-5p and HMGB1 was explored by flow cytometry. Results showed that microRNA-181a-5p was significantly down-regulated by D-GalN/LPS in vivo and in vitro, while the level of HMGB1 was up-regulated after the challenge. Furthermore, microRNA-181a-5p overexpression attenuated cell apoptosis in D-GalN/TNF-treated BNLCL2 cells. MicroRNA-181a-5p could directly target HMGB1 mRNA and repress its expressions, in further HMGB1 is involved in microRNA-181a-5p effect on cell apoptosis of ALF. In conclusion, these findings demonstrate that microRNA-181a-5p regulates hepatocyte apoptosis via HMGB1 in the development of ALF, which may provide potential therapeutic targets for ALF. However, the precise underlying mechanism that connects microRNA-181a-5p and HMGB1 remains to be explored.
Assuntos
Proteína HMGB1 , Falência Hepática Aguda , MicroRNAs , Animais , Camundongos , Apoptose/genética , Galactosamina , Proteína HMGB1/genética , Proteína HMGB1/metabolismo , Lipopolissacarídeos , Falência Hepática Aguda/genética , Falência Hepática Aguda/metabolismo , Análise em Microsséries , MicroRNAs/genética , MicroRNAs/metabolismoRESUMO
BACKGROUND: Ferroptosis and mitochondria-mediated apoptosis are both involved in the pathogenesis of acute liver failure (ALF). Ferroptosis-produced reactive oxygen species (ROS) trigger the chain oxidation of polyunsaturated phospholipids and promote mitochondrial apoptosis. Dihydroquercetin (DHQ) also plays an important protective role against liver injury. PURPOSE: Here, we aimed to investigate the protective effects of DHQ on ALF. We also explored the underlying mechanism. METHODS: We established a Lipopolysaccharide (LPS)/D-galactosamine (D-Gal)-induced ALF mouse model and tumor necrosis factor-α (TNF-α)/D-Gal-induced ALF LO2 cell model. 2',7'-Dichlorofluorescein diacetate (DCFH-DA) and Dihydroethidium (DHE) were used to detect total ROS levels. Lipid ROS was assessed using C11-BODIPY flow cytometry. Lipid peroxidative products levels were detected using MDA ELISA assay and 4-hydroxynonenal (4-HNE) immunohistochemistry. QRT-PCR and western blots were used to test mRNA and protein expression levels, respectively. Cell viability was evaluated with CCK8 assay, and apoptosis was analyzed using flow cytometry. RESULTS: DHQ treatment improved LPS/D-Gal-induced ALF, as well as TNF-α/D-Gal-induced reductions in LO2 viability and increased sirtuin 1 (SIRT1) expression. DHQ pretreatment also reduced the accumulation of ROS, reduced lipid peroxidation, elevated mitochondrial membrane potentials (ΔΨm), and decreased liver cell apoptosis both in vivo and in vitro. Additionally, the knockdown of SIRT1 and p53 activator (Tenovin-6) treatment reversed DHQ's inhibitory effects on ferroptosis and mitochondria-mediated apoptosis in vitro. DHQ enhanced p53 deacetylation by both up-regulating SIRT1 expression and directly bonding to SIRT1. We also found that Tenovin-6's stimulatory effects on ferroptosis and mitochondria-mediated apoptosis in the DHQ-treated LO2 ALF cell model were partially attenuated by overexpression of solute carrier family 7member 11 (SLC7A11), as well as by apoptotic protease activating factor 1 (Apaf-1) knockdown. CONCLUSION: Our results suggest that DHQ alleviated ALF by inhibiting both ferroptosis and mitochondria-mediated apoptosis by regulating the SIRT1/p53 axis. Thus, DHQ may serve as a novel therapy for ALF.
Assuntos
Apoptose , Ferroptose , Falência Hepática Aguda , Quercetina , Sirtuína 1 , Proteína Supressora de Tumor p53 , Animais , Humanos , Masculino , Camundongos , Apoptose/efeitos dos fármacos , Linhagem Celular , Modelos Animais de Doenças , Ferroptose/efeitos dos fármacos , Galactosamina , Peroxidação de Lipídeos/efeitos dos fármacos , Lipopolissacarídeos , Falência Hepática Aguda/tratamento farmacológico , Falência Hepática Aguda/induzido quimicamente , Camundongos Endogâmicos C57BL , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Quercetina/farmacologia , Quercetina/análogos & derivados , Espécies Reativas de Oxigênio/metabolismo , Sirtuína 1/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Proteína Supressora de Tumor p53/metabolismoRESUMO
Oxygen evolution reaction is an essential but kinetically sluggish step in many energy storage and conversion processes and therefore is in pursuit of highly efficient and stable catalysts. Although nanosized transition-metal-based oxides/hydroxides exhibit high catalytic activity toward the oxygen evolution reaction (OER), many of them suffer from low stability at an anode current density in industrial scale. Herein, by combining a rapid epitaxial formation method with dynamic bubble-templated electrodeposition, we successfully developed single crystalline NiFeCu oxide catalysts with a hierarchical porous structure. It was found that the structure can facilitate fast electron transportation for the catalysts and retard the diffusion of the O atoms to the inner metallic current collector. The hierarchical pores inherited from the hydrogen bubble templates built ideal channels for the massive and rapid release of oxygen bubbles. As a consequence, the NiFeCu oxides catalyzed the OER more efficiently and steadily than the commercial RuO2 catalyst at an anode current density in industrial scale (300 mA/cm2). This work, by resolving the durability concerns for nanosized oxides, offers a series of highly efficient and stable catalysts for OER and a structure building strategy to boost the catalytic activity and stability for nonconductive catalysts.